^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    albumin-bound docetaxel (CPO100)

    i
    Other names: CPO-100, HB1801, CPO100, docetaxel nanoparticle formulated with human albumin, DTX-HSA
    Associations

    News

    Trials
    Company:
    CSPC Pharma
    Drug class:
    Tubulin polymerization promoter, Microtubule stabilizer
    Related drugs:
    Associations

    News

    Trials
    19h
    A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer (clinicaltrials.gov)
    P3, N=630, Recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Enrolling by invitation --> Recruiting
    Enrollment status
    |
    albumin-bound docetaxel (CPO100)
    2ms
    A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer (clinicaltrials.gov)
    P3, N=630, Enrolling by invitation, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting --> Enrolling by invitation
    Enrollment open
    |
    albumin-bound docetaxel (CPO100)
    3ms
    CPO-100-US-101: Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=126, Active, not recruiting, Conjupro Biotherapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    albumin-bound docetaxel (CPO100)
    4ms
    A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=256, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    New P2 trial • Metastases
    |
    Haiyitan (gumarontinib) • albumin-bound docetaxel (CPO100)
    4ms
    A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov)
    P3, N=142, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    New P3 trial • Metastases
    |
    albumin-bound docetaxel (CPO100)
    8ms
    A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer (clinicaltrials.gov)
    P3, N=630, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    New P3 trial
    |
    albumin-bound docetaxel (CPO100)
    11ms
    A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma. (clinicaltrials.gov)
    P1/2, N=129, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • paclitaxel • Enshuxing (enlonstobart) • albumin-bound docetaxel (CPO100)
    12ms
    A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma. (clinicaltrials.gov)
    P1/2, N=129, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    New P1/2 trial • Combination therapy • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • paclitaxel • Enshuxing (enlonstobart) • albumin-bound docetaxel (CPO100)
    1year
    A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=80, Recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK fusion • ROS1 fusion • ALK-ROS1 fusion
    |
    docetaxel • albumin-bound docetaxel (CPO100)
    over1year
    A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    New P2 trial • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK fusion • ROS1 fusion • ALK-ROS1 fusion
    |
    docetaxel • albumin-bound docetaxel (CPO100)
    almost3years
    A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN) (clinicaltrials.gov)
    P1/2, N=94, Recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Nov 2021 --> Feb 2022
    Enrollment open • Trial initiation date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • docetaxel • albumin-bound docetaxel (CPO100)
    3years
    A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) (clinicaltrials.gov)
    P1/2, N=94, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    Clinical • New P1/2 trial • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • docetaxel • albumin-bound docetaxel (CPO100)